Novartis: Pulmonary Disease, Chronic Obstructive trials

The registry lists 117 Pulmonary Disease, Chronic Obstructive studies with Novartis as lead sponsor. 0 are open to participants now and 94 have results posted.

Phase 1 9Phase 2 26Phase 3 61Phase 4 24No phase 2(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICSWithdrawnNCT01757015Phase 3
• Compare the Effect of a Remote Monitoring System Using the EXACT Tool to Reduce Hospitalizations Due to Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. EXACT = Exacerbations of Chronic Pulmonary Disease Tool.CompletedNCT01744028Phase 1
• Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active ControlWithdrawnNCT01715311Phase 4
• Efficacy of Indacaterol 150 µg Versus FormoterolWithdrawnNCT01377428Phase 4
• Efficacy of DNK333 in Patients With COPD and CoughCompletedNCT01287325Phase 1/2
• To Determine the Relationship Between Baseline Reversibility and the Efficacy of IndacaterolCompletedNCT01272362Phase 4
• Cardiac Safety of IndacaterolCompletedNCT01263808Phase 1
• Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01197287Phase 1
• Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01068613Phase 2
• Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT00568503Phase 1
• Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00545311Phase 1
• Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00532350Phase 1
• Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and FormoterolCompletedNCT00422552Phase 1/2
• Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00396604Phase 2/3
• Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary DiseaseCompletedNCT00134979Phase 4
• Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00129831Phase 2
• Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00098228Phase 2